American-Israeli soldier Edan Alexander released after 580 days of Hamas captivity, highlighting the ongoing trauma of hostages and the need for continued international action.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
American-Israeli soldier Edan Alexander released after 580 days of Hamas captivity, highlighting the ongoing trauma of hostages and the need for continued international action.
Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.